Resolution of the Council of Russian Experts: Apremilast, a phosphodiesterase 4 inhibitor, as a representative of a new class of small molecule compounds: Its place in the treatment of moderate or severe psoriasis and psoriatic arthritis

• Main Author: A. A. Kubanov
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2017-03-01
• Series: Современная ревматология
• Subjects: meeting of russian experts; psoriasis; psoriatic arthritis; treatment; phosphodiesterase 4 inhibitor
• Online Access: https://mrj.ima-press.net/mrj/article/view/744

On November 26, 2016, Moscow hosted an Interdisciplinary Council of Russian Experts in Dermatology and Rheumatology, which discussed the unsolved problems and new possibilities of therapy for psoriasis (Ps) and psoriatic arthritis (PsA). The meeting was attended by leading experts in rheumatology and dermatology. The experts analyzed data, including the foreign guidelines relating to the new representative of a class of small molecule compounds, apremilast (registered in the Russian Federation in 2016) in order to determine the place of the drug in algorithms for treatment of moderate and severe Ps and PsA. They came to the following conclusions: the use of apremilast extends the existing possibilities for treating Ps and PsA; the drug can be administered to patients with moderate-to-severe plaque Ps or active PsA in case of the insufficiently efficiency or intolerance of previous therapy with disease-modifying antirheumatic drugs or contraindications to their use. Apremilast may be recommended in patients with concomitant diseases; it is appropriate to carry out a pharmaco-economic analysis and to get experience with apremilast in the healthcare facilities of the Russian Federation.